Meeting
2021 ASCO Annual Meeting
The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT).
Authors
Matthew Scott Ernst
Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada
Matthew Scott Ernst , Sarah Abou Alaiwi , Nazli Dizman , Chris Labaki , Pier Vitale Nuzzo , Elio Adib , Andrew Lachlan Schmidt , Luis A Meza , Chun Loo Gan , J Connor Wells , Ziad Bakouny , Sumanta K. Pal , Toni K. Choueiri , Daniel Yick Chin Heng , Shaan Dudani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4552)
DOI
10.1200/JCO.2021.39.15_suppl.4552
Abstract #
4552
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of neutrophil to eosinophil ratio (NER) with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with first-line (1L) immune checkpoint inhibitors (ICI) –based regimens.
First Author: Marc Eid
Poster
2023 ASCO Genitourinary Cancers Symposium
Clinical outcomes of patients with bone-predominant metastatic renal cell carcinoma.
First Author: Jinesh S. Gheeya
Poster
2022 ASCO Annual Meeting
Systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of patients with cancer treated with immune checkpoint inhibitors.
First Author: Gerard Zalcman
Poster
2022 ASCO Genitourinary Cancers Symposium
Does concurrent COX inhibition and immune checkpoint blockade improve clinical outcomes in patients with metastatic renal cell carcinoma (mRCC)?
First Author: Premsai Kumar